Vasculitis & polymyalgia rheumatica
Exploring total inflammatory vascular volume as a diagnostic and prognostic biomarker in giant cell arteritis
Authors' conclusion
TIVV and TIGV showed superior diagnostic and prognostic performance compared with conventional PET parameters, underscoring the importance of inflammation volume in evaluating disease activity in LV-GCA.
Study context
- Population
- Patients with active LV-GCA treated with tocilizumab monotherapy for 52 weeks, preceded by three boluses of i.v. methylprednisone
- Participants
- 18 patients61 PET scans
- Exposure
- Total inflammation vascular volume (TIVV) and total inflammation glycolytic volume (TIGV) vs conventional PET parameters
- Outcome
- Association with active disease (disease activity assessment)
Methodological detailsdiagnostic and prognostic biomarker study, 18F-FDG PET/CT at baseline and weeks 24, 52 and 78, Cox proportional hazard model
- Diagnostic and prognostic biomarker study
- 18F-FDG PET/CT at baseline and weeks 24, 52 and 78
- Cox proportional hazard model
Main finding
As reported in the abstract
Association with active disease
Odds ratio (95% CI)
TIVV
4.74(1.23–18.2)
TIGV
5.45(1.36–21.8)
PETVAS
2.16(0.87–5.33)
TVS
1.86(0.76–4.52)
Observational data: associations, not effects.
Further findings
Time to relapse or aortic dilatation (Cox model) · median follow-up of 117 weeks
| HR (95% CI) | ||
|---|---|---|
| TIVV | 2.50 (1.07–5.84) | |
| TIGV | 2.23 (1.04–4.82) | |
| 0.20.5125Hazard ratio (log scale) |
- Time to relapse or aortic dilatation (Cox model) — Events
- 10
Time to relapse or aortic dilatation (Cox model) · median follow-up of 117 weeks
- PETVAS and total vascular score (TVS) exhibited a weaker association with prognosis
Original publication
Exploring total inflammatory vascular volume as a diagnostic and prognostic biomarker in giant cell arteritis. Rheumatology (Oxford). Published 12 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →